Skip to main content
SpringerLink
Log in

Overview of the Tolerability of Gefitinib (IRESSA™) Monotherapy

Clinical Experience in Non-Small-Cell Lung Cancer

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Cytotoxic chemotherapy treatment options for patients with non-small-cell lung cancer (NSCLC) have limited efficacy and are often associated with significant toxicity. Therefore, there is an unmet need for novel drugs that are not only effective in treating this disease but are also well tolerated. Gefitinib is an orally active epidermal growth factor receptor tyrosine kinase inhibitor that blocks the signal transduction pathways implicated in cancer cell growth and survival. It has recently been approved for the treatment of advanced/refractory NSCLC. This review presents the tolerability data from phase I and II gefitinib monotherapy trials, along with data from the worldwide ‘Expanded Access Programme’ and post-marketing use of gefitinib.

Gefitinib was found to be generally well tolerated at the approved dosage of 250 mg/day; the most commonly reported adverse drug reactions (ADRs) were mild to moderate skin rash and diarrhoea, which were manageable and non-cumulative. Other ADRs observed with the use of gefitinib included: dry skin, pruritus, acne, nausea, vomiting, anorexia, asthenia and asymptomatic elevations in liver transaminase levels. Well recognised adverse effects seen with cytotoxic chemotherapy (such as bone marrow depression, neurotoxicity and nephrotoxicity) were not observed. Although the frequency and severity of ADRs increased with the dosage across the range studied (50–1000 mg/day), few patients required dosage reductions or the withdrawal of treatment, and those who did usually received gefitinib ≥600 mg/day.

Thus, the available data indicate that gefitinib is well tolerated in patients with a range of solid tumours, including locally advanced or metastatic NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Table I
Table II
Table III
Fig. 1
Fig. 2
Table IV
Table V
Fig. 3
Table VI

Similar content being viewed by others

References

  1. Ries LAG, Eisner MP, Kosary CL, et al. SEER cancer statistics review, 1975-2001 [online]. Available from URL: http://seer.cancer.gov/csr/1975_2001/ [Accessed 2004 Apr]

  2. Langer CJ, Leighton JC, Comis RL, et al. Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis. J Clin Oncol 1995; 13(8): 1860–70

    PubMed  CAS  Google Scholar 

  3. Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18(1): 122–30

    PubMed  CAS  Google Scholar 

  4. Zalcberg J, Millward M, Bishop J, et al. Phase II study of docetaxel and cisplatin in advanced non-small-cell lung cancer. J Clin Oncol 1998; 16(5): 1948–53

    PubMed  CAS  Google Scholar 

  5. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002; 346(2): 92–8

    Article  PubMed  CAS  Google Scholar 

  6. Fossella FV, Devore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. J Clin Oncol 2000; 18(12): 2354–62

    PubMed  CAS  Google Scholar 

  7. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18(10): 2095–103

    PubMed  CAS  Google Scholar 

  8. Hanna NH, Shepherd FA, Rosell R, et al. A phase III study of pemetrexed vs docetaxel in patients with recurrent non-small cell lung cancer (NSCLC) who were previously treated with chemotherapy [abstract 2503]. Proc Am Soc Clin Oncol 2003; 22: 622

    Google Scholar 

  9. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998; 317(7161): 771–5

    Article  PubMed  CAS  Google Scholar 

  10. Woodburn JR. The epidermal growth factor receptor and its inhibition in cancer therapy. Pharmacol Ther 1999; 82(2-3): 241–50

    Article  PubMed  CAS  Google Scholar 

  11. Aaronson SA. Growth factors and cancer. Science 1991; 254(5035): 1146–53

    Article  PubMed  CAS  Google Scholar 

  12. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res 2002; 62(20): 5749–54

    PubMed  CAS  Google Scholar 

  13. National Cancer Institute Cancer Therapy Evaluation Program. Common toxicity criteria manual. Common toxicity criteria, version 2.0 [online]. Available from URL: http://ctep.info.nih.gov/ 1999 [Accessed 2004 Apr]

  14. Schultz G, Cipolla L, Whitehouse A, et al. Growth factors and corneal endothelial cells: III. Stimulation of adult human corneal endothelial cell mitosis in vitro by defined mitogenic agents. Cornea 1992; 11(1): 20–7

    Article  PubMed  CAS  Google Scholar 

  15. AstraZeneca studies TAD/876 (Jan 1997), TAR/2570 (Jan 1997), TPD/877 (Aug 1998). (Data on file)

  16. AstraZeneca study TAD/876 (Jan 1997). (Data on file)

  17. Nakagawa K, Tamura T, Negoro S, et al. Phase I pharmacokinetic trial of the selective oral epidermal growth factor receptor tyrosine kinase inhibitor gefitinib (‘Iressa’, ZD1839) in Japanese patients with solid malignant tumours. Ann Oncol 2003; 14(6): 922–30

    Article  PubMed  CAS  Google Scholar 

  18. Ranson M, Hammond LA, Ferry D, et al. ZD1839, a selective oral epidermal growth factor receptor-tyrosine kinase inhibitor, is well tolerated and active in patients with solid, malignant tumors: results of a phase I trial. J Clin Oncol 2002; 20(9): 2240–50

    Article  PubMed  CAS  Google Scholar 

  19. Baselga J, Rischin D, Ranson M, et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol 2002; 20(21): 4292–302

    Article  PubMed  CAS  Google Scholar 

  20. Herbst RS, Maddox AM, Rothenberg ML, et al. Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activity in non-small-cell lung cancer and other solid tumors: results of a phase I trial. J Clin Oncol 2002; 20(18): 3815–25

    Article  PubMed  CAS  Google Scholar 

  21. Swaisland HC, Ranson M, Smith RP, et al. Pharmacokinetic drug interactions with gefitinib (IRESSA, ZD1839) an epidermal growth factor receptor tyrosine kinase inhibitor, during co-administration with rifampicin, itraconazole and metoprolol. Clin Pharmacokinet. In press

  22. Herbst R. Targeting the epidermal growth factor receptor: prognostic and clinical implications. Eur J Cancer Suppl 2003; 1(8): 9–15

    Article  CAS  Google Scholar 

  23. Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003; 21(12): 2237–46

    Article  PubMed  CAS  Google Scholar 

  24. Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 2003; 290(16): 2149–58

    Article  PubMed  CAS  Google Scholar 

  25. AstraZeneca Drug Safety, 1 Sep 2004. (Data on file)

  26. Forsythe B, Faulkner K. Safety and tolerability of gefitinib (‘IRESSA’, ZD 1839) in advanced NSCLC: overview of clinical experience poster P327. 13th European Respiratory Society Annual Congress; 2003 Sep 27–Oct 1; Vienna

  27. Full prescribing information for IRESSA. AstraZeneca Pharmaceuticals LP, Wilmington (DE), USA

  28. Laight A, Swaisland HC, Partridge EA, et al. Metabolism of [14C]-ZD1839 (’Iressa’) in healthy male volunteers [poster 95]. 26th European Society for Medical Oncology Congress; 2002 Oct 18–22; Nice

  29. Twelves C, White J, Harris A, et al. A phase I pharmacokinetic and tolerability trial of ZD1839 (‘Iressa’) in hepatically impaired patients with solid tumors [poster 339]. 38th American Society of Clinical Oncology Annual Meeting; 2002 May 18–21; Orlando

  30. Swaisland HC, Ranson M, Smith R, et al. Clinical drug interactions with ZD1839 (‘Iressa’), a selective epidermal growth factor receptor tyrosine kinase inhibitor [poster 97]. 26th European Society for Medical Oncology Congress; 2002 Oct 18–22; Nice

  31. AstraZeneca report: A combined population analysis of trials ZD1839IL/0016 and ZD1839IL/0039, Feb 2002. (Data on file)

  32. Cappuzzo F, Bartolini S, Ceresoli GL, et al. Efficacy and tolerability of gefitinib in pretreated elderly patients with advanced non-small-cell lung cancer (NSCLC). Br J Cancer 2004; 90(1): 82–6

    Article  PubMed  CAS  Google Scholar 

  33. Coplin MA, Kommareddy A, McLeod H, et al. Gefitinib (‘Iressa’, ZD1839) shows activity and is well tolerated in elderly patients with non-small-cell lung cancer (NSCLC) [poster 3048]. 39th American Society of Clinical Oncology Annual Meeting; 2003 May 31–Jun 3; Chicago

  34. Gridelli C, Maione P, Castaldo V, et al. Gefitinib in elderly and unfit patients affected by advanced non-small-cell lung cancer. Br J Cancer 2003; 89(10): 1827–9

    Article  PubMed  CAS  Google Scholar 

  35. Soto Parra H, Cavina R, Zucali P, et al. Gefitinib in elderly patients with progressive, pretreated, non-small-cell lung cancer: results from the Istituto Clinico Humanitas [poster]. 10th World Congress on Lung Cancer; 2003 Aug 10–14; Vancouver

  36. Herbst RS, LoRusso PM, Purdom M, et al. Dermatologic side effects associated with gefitinib therapy: clinical experience and management. Clin Lung Cancer 2003; 4(6): 366–9

    Article  PubMed  CAS  Google Scholar 

  37. Bhatia S, Hanna N, Ansari R, et al. A phase II study of weekly gemcitabine and paclitaxel in patients with previously untreated stage IIIb and IV non-small cell lung cancer. Lung Cancer 2002; 38(1): 73–7

    Article  PubMed  Google Scholar 

  38. Seto T, Yamamoto N. Interstitial lung diseases (ILD) induced by gefitinib in patients with advanced non-small cell lung cancer (NSCLC): results of a West Japan Thoracic Oncology Group (WJTOG) epidemiological survey [abstract 7064]. Proc Am Soc Clin Oncol 2004; 23: 629

    Google Scholar 

  39. Health Canada. Health Canada endorsed important safety information on ARAVA (leflunomide). Arava® (leflunomide) and interstitial lung disease [online]. Available from URL: http://www.hc-sc.gc.ca/hpfb-dgpsa/tpd-dpt/arava_hpc_e.html/2004 [Accessed 2004 Oct]

  40. Koo L, Clark J, Higenbottam T, et al. National differences in reporting ‘pneumonia’ and ‘pneumonia interstitial’: an analysis of the WHO adverse events database on 15 drugs in 9 countries for 7 pulmonary conditions. Pharmacoepidemiol Drug Saf 2004; 13Suppl. 1: S31–2

    Google Scholar 

  41. Ma Y, Seneviratne CK, Koss M. Idiopathic pulmonary fibrosis and malignancy. Curr Opin Pulm Med 2001; 7(5): 278–82

    Article  PubMed  CAS  Google Scholar 

  42. Chen Y-M, Perng R-P, Yang K-Y, et al. A multicenter phase II trial of vinorelbine plus gemcitabine in previously untreated inoperable (stage IIIB/IV) non-small cell lung cancer. Chest 2000; 117(6): 1583–9

    Article  PubMed  CAS  Google Scholar 

  43. Rebattu P, Quantin X, Ardiet C, et al. Dose-finding, pharmacokinetic and phase II study of docetaxel in combination with gemcitabine in patients with inoperable non-small cell lung cancer. Lung Cancer 2001; 33(2-3): 277–87

    Article  PubMed  CAS  Google Scholar 

  44. Thomas AL, Cox G, Sharma RA, et al. Gemcitabine and paclitaxel associated pneumonitis in non-small cell lung cancer: report of a phase I/II dose-escalating study. Eur J Cancer 2000; 36(18): 2329–34

    Article  PubMed  CAS  Google Scholar 

  45. Willner J, Schmidt M, Kirschner J, et al. Sequential chemo- and radiochemotherapy with weekly paclitaxel (Taxol®) and 3D-conformal radiotherapy of stage III inoperable non small cell lung cancer: results of a dose escalation study. Lung Cancer 2001; 32(2): 163–7136

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

We would Like to thank all investigators who participated in the studies.

Author information

Authors and Affiliations

  1. Drug Safety, AstraZeneca, Parklands, Alderley Park, Macclesfield, Cheshire, SK10 4TP, UK

    Beverley Forsythe & Karen Faulkner

Authors
  1. Beverley Forsythe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Karen Faulkner
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Beverley Forsythe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Forsythe, B., Faulkner, K. Overview of the Tolerability of Gefitinib (IRESSA™) Monotherapy. Drug-Safety 27, 1081–1092 (2004). https://doi.org/10.2165/00002018-200427140-00002

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200427140-00002

Keywords

Search

Navigation